Table 2 Univariate Analysis
Outcomes | N Eval | Prob (95% CI) |
|---|---|---|
Neutrophil engraftment | 236 | Â |
 1-year |  | 97 (94–99)% |
 2-year |  | 97 (94–99)% |
Platelet recovery | 218 | Â |
 1-year |  | 91 (87–94)% |
 2-year |  | 91 (87–95)% |
Acute GVHD (II-IV) | 239 | Â |
 180-day |  | 36 (30–42)% |
Acute GVHD (III-IV) | 229 | Â |
 180-day |  | 12 (8–17)% |
Chronic GVHD | 230 | Â |
 1-year |  | 49 (43–56)% |
 2-year |  | 58 (51–64)% |
Extensive cGVHD | 230 | Â |
 1-year |  | 39 (33–46)% |
 2-year |  | 46 (39–53)% |
GRFS | 230 | Â |
 1-year |  | 35 (29–41)% |
 2-year |  | 27 (21–33)% |
NRM | 249 | Â |
 1-year |  | 19 (14–24)% |
 2-year |  | 25 (20–31)% |
 4-year |  | 30 (24–36)% |
Progression/relapse | 249 | Â |
 1-year |  | 15 (11–20)% |
 2-year |  | 19 (15–25)% |
 4-year |  | 21 (16–27)% |
PFS | 249 | Â |
 1-year |  | 66 (60–72)% |
 2-year |  | 56 (49–62)% |
 4-year |  | 47 (41–54)% |
Overall survival | 249 | Â |
 1-year |  | 73 (68–79)% |
 2-year |  | 63 (56–69)% |
 4-year |  | 56 (49–63)% |